HOME >> MEDICINE >> NEWS
AMPAKINE compounds a new potential treatment for respiratory depression

was intended.

The drug tested in this study belongs to a novel class of molecules known as AMPAKINE compounds being developed by Cortex Pharmaceuticals, Inc. located in Irvine, California. AMPAKINE compounds act on the most common excitatory receptor in the brain, the AMPA "Glutamate type receptor," which has been shown in rodent models to boost the brain's own protein for improving age-related deficits in memory mechanisms. In primate models AMPAKINE compounds have replicated the studies in rodents and in adults patients suffering from Attention Deficit Hyperactivity Disorder, significant clinical and statistical improvement in increase attention and decrease hyperactivity have been observed. The U. Alberta research provide evidence that another important AMPAKINE indication is to stimulate primitive areas of the brain called the pre-Botzinger Complex responsible for breathing, without causing side effects. The pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties that have been identified in this brain region.

In a study published in 2006, Dr. John J. Greer of U. Alberta demonstrated that certain AMPAKINE compounds enhance the respiratory drive and breathing rhythm at the brain-stem level containing the pre-Botzinger Complex in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants.

Dr. Greer found that respiratory depression induced by these agents can be reversed or prevented in test animals with an experimental AMPAKINE drug, without a reduction of pain relief or sedation.

Greer and coworkers treated rats with the opioids analgesic fentanyl or the barbiturate sedative Phenobarbital, both commonly prescribed in the United States. Greer used a technique known as plethysmography, which measures blood flow throughout
'"/>

Contact: Mark Varney
mvarney@cortexpharm.com
949-231-0672
Cortex Pharmaceuticals
4-Jun-2007


Page: 1 2 3 4 5

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
3. U of M researchers discover compounds to shrink tumors
4. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue
5. New compounds fight chronic symptoms of bowel disorders
6. New synthetic compounds appear to prevent brain cell death
7. Phenolic compounds may explain Mediterranean diet benefits
8. Vitamin D compounds show promise for prevention of prostate cancer
9. Hebrew University researcher develops compounds to control bacteria
10. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
11. Electric fields have potential as a cancer treatment

Post Your Comments:
(Date:7/25/2014)... July 25, 2014 Splashtop, Inc. announced ... Program . Splashtop Business and Splashtop Enterprise will now ... will leverage the MaaS360 WorkPlace SDK to enable enterprise-grade ... Business and Splashtop Enterprise offer secure remote access, support, ... High performance, ease of use, collaborative features, and ...
(Date:7/25/2014)... 2014 Training Mask LLC, is proud ... an endorsement agreement to promote the mask and its’ ... for over 10 years, and ran over 30 ultra ... of the Angeles Crest 100-mile endurance run. Brian is ... of the endurance, strength and conditioning paradigm. He created ...
(Date:7/25/2014)... An alpha olefin is an olefin or an ... alpha position of the carbon chain, or between the 1st ... namely, branched and linear (or normal). The alpha olefin market ... its applications such as polyethylene co-monomers and synthetic lubricants, across ... Europe have been lucrative markets for alpha olefins; however, Asia-Pacific ...
(Date:7/25/2014)... -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... Patent Pool (MPP) and Gilead Sciences, Inc. to ... promising new HIV medication. The agreement was announced ... in Melbourne, Australia. , While TAF is ... suggests it could be a key ingredient in ...
(Date:7/25/2014)... 2014 Ross A. Clevens, MD, FACS, ... to join the exclusive Obagi Clinical Advisory Board, comprised ... surgeons, plastic surgeons and dermatologists. , Dr. Clevens ... Board of thought leaders held its first meeting in ... to give Obagi the opportunity to meet with eight ...
Breaking Medicine News(10 mins):Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 2Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 3Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2
(Date:7/24/2014)... July 24, 2014  Kinex Pharmaceuticals announced the receipt ... Company,s KX2-391 Ointment for the commencement of a Phase ... Company,s third IND to be allowed by the US ... is a synthetic, orally active and highly selective inhibitor ... promotes the induction of p53, G2/M arrest of proliferating ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... Research and Markets  has announced the ... Product, Component, Application and Geography - Global Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 ... a moderate growth as the markets of the U.S. ... the saturation levels. The demand is expected to come ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
Cached News: